Introduction {#s1}
============

The evolution of more than 500 human protein kinases from a few protein kinases in unicellular organisms allowed for the development of complexity via differential regulation ([@bib73]). Such regulation can be achieved by autophosphorylation or interactions with other domains or binding partners. While many of the signaling cascades and their in vivo biological effectors have been well characterized, and a wealth of structural information is available ([@bib52]; [@bib49]; [@bib73]; [@bib102]), the molecular mechanism whereby kinase activity is modulated is a topic of controversial debate ([@bib82]; [@bib23]). Here we investigate two fundamentally distinct regulation mechanisms by characterizing autophosphorylation of Aurora A as well as activation by TPX2 (Targeting Protein for Xklp2). Aurora A, a Ser/Thr kinase, is a key regulator of mitotic events, including mitotic entry ([@bib72]; [@bib92]), centrosome maturation ([@bib41]; [@bib45]; [@bib96]; [@bib1]; [@bib78]), and spindle formation ([@bib39]; [@bib56]; [@bib99]; [@bib59]; [@bib104]; [@bib109]; [@bib113]). Aurora A depletion leads to cell cycle arrest, while overexpression has been found in many cancer cell lines ([@bib54]; [@bib93]; [@bib115]; [@bib51]). Therefore extensive interest has been recently directed towards Aurora A for anti-cancer drug development ([@bib4]; [@bib11]; [@bib18]). TPX2 recruits Aurora A to the spindle microtubules, an event that is essential in spindle formation ([@bib62]; [@bib40]).

Autophosphorylation of T288 in the activation loop increases the catalytic activity of Aurora A ([@bib105]; [@bib66]). Intramolecular autophosphorylation has recently been suggested for Aurora A and Chk2 based on indirect kinetic measurements ([@bib23]) adding to the controversy by disagreeing with the intermolecular mechanism proposed for other protein kinases ([@bib82], [@bib83]; [@bib86]; [@bib64]).

A second puzzling result has also been reported recently. It was shown that in vivo during mitosis, TPX2-bound Aurora A at the spindle microtubules is dephosphorylated at the crucial T288 ([@bib97]). Since T288-dephosphorylated Aurora A exhibits very low kinase activity, a second kinase-independent function of Aurora A was postulated (Littlepage, 2002). There is evidence suggesting that TPX2 also plays an active role in upregulating Aurora A activity, however the interplay between the two distinct activation mechanisms, phosphorylation and TPX2-binding, is not well understood ([@bib62]; [@bib14]; [@bib32]; [@bib35]; [@bib63]; [@bib98]; [@bib100]; [@bib10]; [@bib13]; [@bib33]; [@bib84]; [@bib99]; [@bib5]). Here we address both controversies by directly measuring autophosporylation and by characterizing the molecular mechanism of Aurora A regulation by TPX2.

Results and discussion {#s2}
======================

Phosphorylation of T288 in Aurora A or TPX2 binding results in comparable increases in catalytic activity {#s2-1}
---------------------------------------------------------------------------------------------------------

While it is generally accepted that phosphorylation of a Ser/Thr in the activation loop activates Ser/Thr kinases, this regulation has not been characterized quantitatively. Part of the difficulty consists in obtaining a dephosphorylated protein, since *Escherichia coli*-produced kinases are heavily phosphorylated due to autophosphorylation and phosphorylation by *E. coli* kinases during expression ([@bib29]) ([Figure 1A](#fig1){ref-type="fig"}).10.7554/eLife.02667.003Figure 1.TPX2^1−45^ drastically accelerates the kinetics of the dephosphorylated form of Aurora A kinase.(**A**) Mass spectrometry data of heavily phosphorylated (P) and dephosphorylated (deP) Aurora A. The dephosphorylated protein was obtained after treatment of heavily phosphorylated, *Escherichia coli-*produced Aurora A with λ-protein phosphatase (λPP). (**B**) AP phosphorylation by dephosphorylated (![](elife02667inf001.jpg), 0.01 ± 0.005 s^−1^) or T288V mutant Aurora A (![](elife02667inf002.jpg), 0.05 ± 0.002 s^−1^) is increased by up to 50-fold (![](elife02667inf003.jpg), 0.5 ± 0.1 s^−1^) and 25-fold (![](elife02667inf004.jpg), 1.2 ± 0.1 s^−1^), respectively, in the presence of TPX2^1−45^. This rate is comparable to the kinetics of phosphorylated Aurora A in the absence of TPX2^1−45^ (![](elife02667inf005.jpg), 1.0 ± 0.2 s^−1^). Phosphorylated Aurora A shows up to a twofold increase in AP kinetics in the presence of TPX2^1−45^ (![](elife02667inf006.jpg), 2.3 ± 0.2 s^−1^). Reactions are carried out in the presence of 1 μM protein, 50 μM TPX2^1−45^, 5 mM ATP, and 1 mM AP in assay buffer (20 mM TrisHCl, 200 mM NaCl, 20 mM MgCl~2~, 3% (vol/vol) glycerol, 1 mM TCEP, pH 7.50) at 25°C. Phosphorylated peptide production was monitored by reverse phase-high performance liquid chromatography (RP-HPLC).**DOI:** [http://dx.doi.org/10.7554/eLife.02667.003](10.7554/eLife.02667.003)10.7554/eLife.02667.004Figure 1---figure supplement 1.Kinase assays were conducted under saturating conditions of peptide and ATP.To ensure peptide and nucleotide would not be rate-limiting, (**A**) the K~M~ for AP was determined to be 116 ± 70 μM for phosphorylated Aurora A (left) and 320 ± 150 μM for dephosphorylated-mimic, T288V mutant Aurora A (right) and (**B**) the kinetics of 10 μM Aurora A T288V were monitored under 1 mM AP at 5 mM ATP (![](elife02667inf007.jpg), 0.0054 s^−1^) and 15 mM ATP (![](elife02667inf008.jpg), 0.0055 s^−1^) as well as 2 mM AP and 15 mM ATP (![](elife02667inf009.jpg), 0.0056 s^−1^). In each case, the kinetics of AP phosphorylation were identical within experimental error. Since the K~M~ for ATP for WT Aurora A is about 10 μM ([@bib57]), all following kinetic reactions were run at 5 mM ATP (20 mM TrisHCl, 200 mM NaCl, 20 mM MgCl~2~, 3% \[vol/vol\] glycerol, 1 mM TCEP, pH 7.50) at 25°C. Phosphorylated peptide production was monitored by reverse phase-high performance liquid chromatography (RP-HPLC).**DOI:** [http://dx.doi.org/10.7554/eLife.02667.004](10.7554/eLife.02667.004)10.7554/eLife.02667.005Figure 1---figure supplement 2.Aurora A exhibits the same activity towards AP whether the protein is phosphorylated on multiple sites or singly phosphorylated on T288.The rates are 0.93 s^−1^ and 0.97 s^−1^, respectively. To obtain singly phosphorylated Aurora A (1P_AurA) , dephosphorylated protein was autophosphorylated in the presence of ATP and a final concentration of 1 μM of this protein was used for the assay described here. Aurora A phosphorylated on multiple sites (mP_AurA) was obtained through classic expression in *Escherichia coli* cells (see [Figure 1A](#fig1){ref-type="fig"}). Reactions were carried out in the presence of 5 mM ATP and 1 mM AP in assay buffer at 25°C.**DOI:** [http://dx.doi.org/10.7554/eLife.02667.005](10.7554/eLife.02667.005)10.7554/eLife.02667.006Figure 1---figure supplement 3.Aurora A kinase autophosphorylation and substrate phosphorylation were simultaneously followed either in the absence or presence of TPX2^1−45^.In the experiments aimed at measuring activity of AP phosphorylation of dephosphorylated Aurora A ([Figure 1B](#fig1){ref-type="fig"}), autophosphorylation can occur during the time-course of the reaction. Therefore autophosphorylation of 1 μM Aurora A in the presence of 1 mM AP and 5 mM ATP and in the absence or presence of 50 μM TPX2^1−45^ was monitored simultaneously with AP phosphorylation. Densitometry analysis (left) of raw Western blot data (right) is shown. To account for Aurora A\'s dynamic range, time points up to 300 s were diluted 50× and the rest of the time points were diluted 225×. The amount of phosphorylated protein made during the reaction accounts for only 10% of the detected rate acceleration of AP phosphorylation in the presence of TPX2.**DOI:** [http://dx.doi.org/10.7554/eLife.02667.006](10.7554/eLife.02667.006)10.7554/eLife.02667.007Figure 1---figure supplement 4.TPX2^1−45^ drastically accelerates the kinetics of the dephosphorylated-like Aurora A species irrespective of the nature of the peptide used.TPX2 increases the kinetics of the dephosphorylated-protein mimic (T288V mutant) towards the peptides AP (APSSRRTTLCGTL) (left), Kemptide (LRRASLG) (middle), and Lats2^373−387^ (ATLARRDSLQKPGLE) (right) between 20- and 30-fold. Lats2 is an Aurora A substrate important in centrosome maturation, and Kemptide is a synthetic construct generally used as a substrate of cAMP-dependent protein kinase A (PKA), a protein closely related to Aurora A. Reactions are carried out in the presence of 5 mM ATP and 1 mM peptide in assay buffer at 25°C. A longer TPX2 variant (TPX2^1−147^) was used as control to ensure full capture of TPX2 activity by the shorter variant (TPX2^1−45^). P: phosphorylated.**DOI:** [http://dx.doi.org/10.7554/eLife.02667.007](10.7554/eLife.02667.007)10.7554/eLife.02667.008Figure 1---figure supplement 5.Representative RP-HPLC time traces during AP phosphorylation.These traces (**A**) show well resolved non-phosphorylated and phosphorylated peptide peaks at different reaction time points. (**B**) Screenshot of time traces for AP_T287E (left) and AP_T288E (right) phosphorylation show that Aurora A selectively phosphorylates AP on T288. Assays were carried out in the presence of 1 μM phosphorylated Aurora A, 1 mM AP or 1 mM AP_T287E or AP_T288E, 5 mM ATP, at 25°C in kinase assay buffer (20 mM TrisHCl, 200 mM NaCl, 20 mM MgCl~2~, 3% glycerol, 1 mM TCEP, pH 7.50).**DOI:** [http://dx.doi.org/10.7554/eLife.02667.008](10.7554/eLife.02667.008)10.7554/eLife.02667.009Figure 1---figure supplement 6.Dose-dependence of the concentration of TPX2^1−147^ on the phosphorylation kinetics of AP by Aurora A T288V.The calculated K~A~ = 1.0 ± 0.5 μM compared well with the K~D~ = 1.1 ± 0.1 μM obtained from ITC data ([Figure 7A](#fig7){ref-type="fig"}). Assays were carried out in the presence of 1 μM Aurora A T288V, 1 mM AP, increasing concentrations of TPX2^1−147^, 5 mM ATP, at 25°C in kinase assay buffer (20 mM TrisHCl, 200 mM NaCl, 20 mM MgCl~2~, 3% glycerol, 1 mM TCEP, pH 7.50).**DOI:** [http://dx.doi.org/10.7554/eLife.02667.009](10.7554/eLife.02667.009)

Aurora A was co-expressed with the generic Ser/Thr/Tyr phosphatase lambda (λPP) and treated again with λPP after purification to ensure complete dephosphorylation ([Figure 1A](#fig1){ref-type="fig"}). We then measured the enzymatic activity of phosphorylated versus dephosphorylated Aurora A towards AP, a peptide encompassing residues 281--293 of the kinase\'s activation segment. The experiments were conducted under saturating conditions of peptide, ATP, and Mg^2+^, and we ensured that the singly and heavily phosphorylated kinases exhibited similar kinetics ([Figure 1---figure supplement 1 and 2](#fig1s1 fig1s2){ref-type="fig"}).

Phosphorylated Aurora A catalyzes AP phosphorylation 100-fold faster than the dephosphorylated kinase (1.0 ± 0.2 s^−1^ vs 0.01 ± 0.005 s^---1^; [Figure 1B](#fig1){ref-type="fig"}). Since dephosphorylated Aurora A can also autophosphorylate during this experiment, we not only quantified autophosphorylation during the reaction time frame ([Figure 1--figure supplement 3](#fig1s3){ref-type="fig"}), but we also designed a second experiment that eliminates this competing reaction by mutating T288 to V. This mutant shows comparable low activity to the dephosphorylated kinase (k~cat~^AP^ = 0.05 ± 0.002 s^−1^) serving as a control for quantifying the rate acceleration provided by T288 phosphorylation.

Does TPX2 activate Aurora A to the same extent as phosphorylation or are both activation mechanisms additive? We used TPX2^1−45^ in our studies since this fragment was shown to be sufficient for kinase activation ([@bib9]; [@bib13]). Our data suggest the first scenario since AP phosphorylation is stimulated by 50- and 25-fold by TPX2^1−45^ for the dephosphorylated Aurora A and T288V Aurora A, respectively ([Figure 1B](#fig1){ref-type="fig"}). The rates of dephosphorylated Aurora A plus TPX2^1−45^ are comparable to that of phosphorylated Aurora A alone. Addition of TPX2 to phosphorylated Aurora A results in only a twofold increase in k~cat~. This effect is independent of the nature of the peptide used ([Figure 1--figure supplement 4](#fig1s4){ref-type="fig"}).

Dephosphorylated Aurora A kinase is in the active conformation when bound to TPX2^1−45^ {#s2-2}
---------------------------------------------------------------------------------------

Having shown kinetically that TPX2 is sufficient to activate dephosphorylated Aurora A similarly to T288 phosphorylation, we next studied the underlying molecular mechanism. We first solved the crystal structure of dephosphorylated Aurora A in the absence and presence of TPX2^1−45^ and bound to an ATP-mimic (β,γ-methyleneadenosine 5′ triphosphate, AMPPCP). The AMPPCP-bound, dephosphorylated Aurora A is monomeric and in an inactive conformation, similar to previously solved structures of the same protein bound to adenosine (PDB ID 1MUO \[[@bib16]\]) or AMPPNP (PDB ID 2C6D \[[@bib46]\]). In contrast, the TPX2-bound Aurora A structure reveals a dimer made by two molecules of Aurora A, TPX2, and AMPPCP in the asymmetric unit ([Figure 2A](#fig2){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}).10.7554/eLife.02667.010Figure 2.Dephosphorylated Aurora A adopts an active conformation in the presence of TPX2^1−45^.(**A**) Dephosphorylated Aurora A + TPX2^1−45^ + AMPPCP and (**B**) superposition of Aurora A moieties. (**C**) A detailed view of structural elements that define an active Aurora A kinase: the nucleotide binding region (top inset) and the regulatory spine (bottom inset). Dephosphorylated (deP) Aurora A in the presence of TPX2 (red, PDB ID 4C3P) superposes very well to the phosphorylated (P) Aurora A either in the absence (orange, PDB ID 1OL7) or presence of TPX2 (yellow, PDB ID 1OL5). For comparison, dephosphorylated Aurora A alone (light blue, PDB ID 4C3R) shows the characteristic features of an inactive kinase.**DOI:** [http://dx.doi.org/10.7554/eLife.02667.010](10.7554/eLife.02667.010)10.7554/eLife.02667.011Table 1.Data collection and refinement statistics**DOI:** [http://dx.doi.org/10.7554/eLife.02667.011](10.7554/eLife.02667.011)deP Aurora A + AMPPCPdeP Aurora A + AMPPCP + TPX2Data collection Space groupP 6~1~ 2 2P 2~1~ 2~1~ 2~1~ Cell dimensions *a, b, c* (Å)83.47, 83.47, 172.6349.93, 86.72, 153.55 α, β, γ (°)90, 90, 12090, 90, 90 Resolution (Å)86.3--2.79 (2.87--2.79)86.7--2.69 (2.76--2.69) *R*~merge~0.08 (2.08)0.26 (3.51) *I/σ*19.8 (1.8)8.0 (2.3) Completeness (%)100 (100)100 (100) Redundancy15.7 (16.7)6.9 (7.2)Refinement Resolution (Å)55.4--2.79 (2.87--2.79)47.5--2.69 (2.76--2.69) No. reflections845918104 *R*~work~*/R*~free~0.221/0.306 (0.327/0.451)0.201/0.289 (0.284/0.400) No. atoms Protein20744574 Ligand/ion3167 Water021 *B*-factors Protein100.354.6 Ligand/ion109.162.5 WaterNA43.3 R.m.s deviations Bond lengths (Å)0.0100.011 Bond angles (°)1.541.53PDB ID4C3R4C3P[^3][^4]

Since the classic bilobal fold of protein kinases is by now well known from many elegant structural studies ([@bib16]; [@bib9]), and our structure in the absence of TPX2 does not provide new information, we will only discuss novel insights gained from the TPX2-bound dephosphorylated Aurora A dimer.

Superposition of the Aurora A monomers shows that they are similar, but not identical within the heterodimer, with implications for autophosphorylation discussed below ([Figure 2B](#fig2){ref-type="fig"}). Interestingly, both monomers are in an active conformation despite being dephosphorylated ([Figure 2C](#fig2){ref-type="fig"}), a feature that has never been seen before in Aurora kinases. Comparison of dephosphorylated Aurora A in the absence or presence of TPX2 reveals subtle but significant interactions by which TPX2 stabilizes the active form of the kinase ([Figure 2C](#fig2){ref-type="fig"}).

First, binding of TPX2 causes a slight rotation of the αC-helix towards the catalytic center, thus allowing for the conserved, stabilizing E181-K162 ion pair to form. The αC-helix rotation also results in movement of F275 of the conserved DFG motif from the DFG-out into the DFG-in position ([@bib74]) ([Figure 2C](#fig2){ref-type="fig"}, bottom inset). This positions the catalytic D274 in the correct orientation to carry out phosphoryl transfer.

Second, movement of F275 initiates a cascade of side chain interactions that result in the completion of the regulatory spine originating from the αF-helix (R-spine; [Figure 2C](#fig2){ref-type="fig"}, bottom inset). Identification of the completed R-spine, a hallmark of an active kinase, is based on the Local Spatial Patterns (LSP) alignment, a bioinformatics tool developed by the Taylor laboratory ([@bib61]). From these structural features it appears that Aurora A, despite being dephosphorylated, is in an active conformation when bound to TPX2. We note that [@bib9] propose that the structure of phosphorylated Aurora A represents a partially active state because the authors interpret the activation segment to be in an inactive conformation as defined by the exposure of pThr288 to the solvent ([@bib9]). We would rather interpret that structure as an active state based on all hallmarks for active kinases ([@bib61]), in agreement with our activity data ([Figure 1B](#fig1){ref-type="fig"}).

Does active, domain-swapped Aurora A dimer capture an enzyme/substrate complex for autophosphorylation? {#s2-3}
-------------------------------------------------------------------------------------------------------

The final signatures for an active state Ser/Thr kinase involve changes around the activation segment. Formation of the β6/β9 antiparallel β sheets, that are not present in the inactive kinase, prime the MgATP for catalysis together with the other conformational changes described above. Finally, the correct positioning of D256 for activating the hydroxyl of the substrate in active Aurora A is achieved by a hydrogen bond network to T292, which in turn H-bonds to K258 with distances shown in [Figure 3A](#fig3){ref-type="fig"}. All these features are fully conserved among eukaryotic Ser/Thr kinases ([@bib80]).10.7554/eLife.02667.012Figure 3.TPX2-bound domain-swapped Aurora A captures an enzyme--substrate complex.(**A**) Left: in the presence of TPX2^1−45^, the N-terminal (β6 and β9 sheets) anchor point of the activation loop is present in both monomers whereas the C-terminal H-bond contacts typical for a fully active kinase (between D256/K258 and T292-OH) are only visible for the enzyme monomer in red, which we therefore define as the enzyme molecule. Right: for comparison, in the absence of TPX2^1−45^, the N- and C-terminal anchor points are not present and the protein is in an inactive state. Interactions that further stabilize the swapped dimer (W313-P297/P298 and R371-E299) are shown in the bottom inset, highlighting that these intermolecular interactions (left) are identical to the corresponding intramolecular interactions (right). (**B**) The loop spanning residues 283--288 in monomer II, for which there was too weak electron density, was remodeled using the software Modeller and biased molecular dynamics. The loop can be arranged by TMD so that the distance between T288 of monomer II and γ-phosphate of AMPPCP of monomer I is compatible with phosphoryl transfer.**DOI:** [http://dx.doi.org/10.7554/eLife.02667.012](10.7554/eLife.02667.012)10.7554/eLife.02667.013Figure 3---figure supplement 1.Comparison of the dimeric Aurora A + TPX2 structure with other domain-swapped Ser/Thr kinases.The activation loop and αEF-helix of one of the monomers nestle between the αF- and αG-helices of the other monomer in the dimer structures. Shown are SLK phosphorylated or non-phosphorylated (PDB IDs 2JFL and 2J51, respectively, both bound to triazole inhibitor DKI), Chk2 (PDB ID 2CN5 bound to ADP), LOK (PDB ID 2 J7T bound to SU11274), DAPK3 (PDB ID 2J90 bound to pyridone 6), p70S6K1 (PDB ID 3A60 bound to staurosporine), and OSR1 (PDB ID 3DAK bound to AMPPNP). One monomer is shown in surface representation and the other in ribbon representation with bound nucleotides shown as sticks (pink). Angles between the monomers and dimeric interface contacts vary significantly.**DOI:** [http://dx.doi.org/10.7554/eLife.02667.013](10.7554/eLife.02667.013)

Curiously, the last two hallmarks of the active state are created by a swap of the activation segments of Aurora A resulting in a dimer conformation that has not been previously reported for this protein. In the C-lobe, W313 that would typically interact with P297 and P298 in monomeric Aurora A, now interacts with the identical Pro residues of the other Aurora A monomer. Lastly, the E299--R371 salt bridge is also domain swapped ([Figure 3A](#fig3){ref-type="fig"}).

Since autophosphorylation is considered a crucial regulation mechanism for protein kinases, the biological meaning of such a dimer structure becomes immediately apparent. While trans-activation through domain-swapped dimers seen in X-ray structures has been proposed for a number of kinases ([Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}) ([@bib82], [@bib83]; [@bib86]; [@bib64]), a recent report on Aurora A and Chk2 suggesting a strict intramolecular autophosphorylation of the activation segment for both enzymes has fueled controversy on this topic ([@bib23]). Another puzzle is the fact that the activation-segment swapped dimers in the literature ([Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}) show both monomers to be either in the inactive or active kinase conformations, and a number of these structures are either bound to an inhibitor or already phosphorylated.

In contrast we find an asymmetric dimer within the unit cell with monomer I showing complete electron density for the activation segment while monomer II is missing residues 283--288 ([Figure 2B](#fig2){ref-type="fig"}, red and blue, respectively). In addition, only monomer I has the perfect geometry of the conserved hydrogen bond network found in a catalytically prone kinase between residues D256, K258, and T292 ([Figure 3A](#fig3){ref-type="fig"}). Therefore we speculated that monomer I may be the enzyme molecule recognizing monomer II as its substrate.

As a first (and only crude) test of this hypothesis, we used targeted MD (TMD) simulations to model the target hydroxyl for autophosphorylation of the domain-swapped activation segment towards the γ-phosphate of AMPPCP ([Figure 3B](#fig3){ref-type="fig"}) to address the question whether it is even physically possible that the hydroxyl can approach the γ-phosphate of AMPPCP. Only T288 of monomer II (proposed as the substrate molecule above) with a more flexible activation loop segment can be rearranged at a close distance to the γ-phosphate of AMPPCP without displacing the AMPPCP from its original position ([Figure 3B](#fig3){ref-type="fig"}).

Functional evidence for intermolecular autophosphorylation within the swapped dimer {#s2-4}
-----------------------------------------------------------------------------------

Neither the crystallographic dimer nor the TMD simulations are compelling evidence for intermolecular autophosphorylation within such a swapped dimer. To answer the first obvious question whether a swapped dimer exists in solution, we performed small-angle X-ray scattering (SAXS) and sedimentation velocity analytical ultracentrifugation (AUC) experiments on dephosphorylated Aurora A in the absence and presence of TPX2 ([Figure 4](#fig4){ref-type="fig"}). A significant amount of dimer was detected for Aurora A and the relative concentration was independent of the presence of TPX2. Importantly, the fact that separate peaks for the dimer and monomer were observed in a sedimentation velocity run reveals a slow interconversion rate between dimer and monomer. Fitting of the SAXS data required inclusion of 9% dimer of the shape of our X-ray structure, supporting the notion that the swapped dimer seen in X-ray crystallography exists in solution in agreement with the AUC data. Protein solubility prohibited determination of the K~D~, but from both the concentration dependence observed in AUC as well as SAXS experiments one can estimate that the K~D~ is above 300 μM.10.7554/eLife.02667.014Figure 4.TPX2-bound domain-swapped Aurora A forms a stable dimer in solution.(**A**) Sedimentation velocity analytical ultracentrifugation data show discrete peaks for monomer and dimer. TPX2^1−25^ does not increase the percentage of Aurora A dimer in solution. It is unclear why there is an increased dimer concentration for the kinase-dead Aurora A D274A mutant. (**B**) Small-angle X-ray scattering (SAXS) data show an increase in dimer concentration with increased Aurora A amounts. All data were collected in the presence of 500 μM AMPPCP in kinase assay buffer. deP, dephosphorylated.**DOI:** [http://dx.doi.org/10.7554/eLife.02667.014](10.7554/eLife.02667.014)

The existence of the dimer in solution is essential but not sufficient for an intermolecular autophosphorylation mechanism. To directly investigate the mechanism, functional assays were performed. First, we designed two Aurora A constructs that differed in activity and length. D274A is a kinase-impaired version ([@bib106]) that is unable to autophosphorylate within our reaction time frame ([Figure 5A](#fig5){ref-type="fig"}, middle panel). Since the N- and C-terminal truncations do not affect activity ([Figure 5--figure supplement 1](#fig5s1){ref-type="fig"}), this trick allowed for easy simultaneous detection of wild type and kinase-impaired Aurora A. While Aurora A^125−392^ D274A cannot phosphorylate itself, equal concentrations of dephosphorylated wild type Aurora A^122−403^ and Aurora A^125−392^ D274A lead to comparable phosphorylation rates for both proteins, demonstrating an intermolecular autophosphorylation mechanism for Aurora A ([Figure 5A](#fig5){ref-type="fig"}, right panel).10.7554/eLife.02667.015Figure 5.Mechanism of autophosphorylation.(**A**) The kinetics of autophosphorylation was monitored by SDS-PAGE and Western blot of 25 μM Aurora A^122−403^ WT or 25 μM Aurora A^125−392^ D274A. WT Aurora A can phosphorylate catalytically dead D274A Aurora A intermolecularly. To account for Aurora A\'s dynamic range, time points up to 300 s were diluted 50-fold and the rest of the time points were diluted 225-fold. (**B**) Dilution to 1 μM protein from a stock solution of 200 μM Aurora A ± TPX2 shows much faster autophosphorylation kinetics than from a lower concentrated stock solution (20 μM ± TPX2) revealing that autophosphorylation occurs within the long-lived dimer. All experiments were carried out at 25°C in kinase assay buffer in the presence of 5 mM ATP.**DOI:** [http://dx.doi.org/10.7554/eLife.02667.015](10.7554/eLife.02667.015)10.7554/eLife.02667.016Figure 5---figure supplement 1.Dephosphorylated Aurora A^125−392^ can autophosphorylate as efficiently as Aurora A^122−403^.SDS-PAGE and Western blot of 25 μM Aurora A^122−403^ WT or 25 μM Aurora A^125−392^ show that both proteins can autophosphorylate to similar extents, suggesting that impaired kinetics in [Figure 5A](#fig5){ref-type="fig"} are due to the D274A mutation and not the length of the protein construct. To account for Aurora A\'s dynamic range, time points up to 300 s were diluted 50× and the rest of the time points were diluted 225×. All experiments were carried out as described in [Figure 5A](#fig5){ref-type="fig"}. deP: dephosphorylated; P: phosphorylated.**DOI:** [http://dx.doi.org/10.7554/eLife.02667.016](10.7554/eLife.02667.016)

The fact that the dimer is long lived as identified by AUC triggered a second independent test of the functional relevance of this swapped dimer. The rate of autophosphorylation was measured for samples of 1 μM Aurora A prepared by dilution from 200 μM and 20 μM stock solutions. Although the final protein concentration in both samples is the same, much faster autophosphorylation was detected for the sample diluted from the more highly concentrated stock solution ([Figure 5A](#fig5){ref-type="fig"}). Since the latter sample contains a higher concentration of this slowly dissociating dimer, this experiment directly demonstrates dimer-dependent autophosphorylation. TPX2 strongly accelerates autophosphorylation, in agreement with previous reports ([@bib35]), and as seen for peptide phosphorylation ([Figure 1B](#fig1){ref-type="fig"} and [Figure 1--figure supplement 4](#fig1s4){ref-type="fig"}). Notably, this intermolecular autophosphorylation again proceeds via the long-lived swapped dimer ([Figure 5B](#fig5){ref-type="fig"}). We note that although necessary, the dimer is not sufficient for autophosphorylation, because the catalytically impaired D274A mutant shows a high percentage of dimer ([Figure 4A](#fig4){ref-type="fig"}). Clearly, TPX2 triggers a conformational change that results in a catalytically active dimer.

As the third line of evidence, we aimed at designing a mutation that would weaken the swapped dimer formation and therefore autophosphorylation without compromising the kinase activity of the phosphorylated monomer towards peptides. Realization of this thought experiment is challenging because most of the intermolecular interactions for the dimer are present as corresponding intramolecular contacts in the monomer ([Figure 3A](#fig3){ref-type="fig"}). We rationalized that a C290A mutation could work because C290 of one monomer contacts Y334 of the αG-helix of the other monomer, while in phosphorylated monomeric Aurora A, C290 contacts K143, W277, L289, and G291 ([Figure 6A,B](#fig6){ref-type="fig"}). The C290A mutation indeed results in a primarily monomeric form ([Figure 6C](#fig6){ref-type="fig"}) that also has severely impaired autophosphorylation activity ([Figure 6D](#fig6){ref-type="fig"}). However, once phosphorylated, C290A has nearly normal catalytic activity towards the AP substrate ([Figure 6E](#fig6){ref-type="fig"}), buttressing the functional role of the swapped WT dimer for autophosphorylation. Particularly striking is the observation that in a 1:1 mixture of dephosphorylated WT and C290A mutant, WT autophosphorylation precedes C290A phosphorylation in the early reaction time course ([Figure 6D](#fig6){ref-type="fig"}, right and inset) but phosphorylation kinetics are identical at later time points. Such kinetic behavior is expected for a model of initial autophosphorylation between two dephosphorylated molecules within the swapped dimer and the subsequent taking over of intermolecular autophosphorylation by newly phosphorylated enzyme molecules. This latter reaction is much faster, suggesting atomistic differences in comparison to the swapped dimer reaction. The C290A mutant is incapable of forming a hybrid swapped dimer between one molecule each of dephosphorylated C290A and WT protein, explaining the lag in its phosphorylation kinetics relative to WT.10.7554/eLife.02667.017Figure 6.A mutant at the dimer interface (C290A) disrupts the swapped-dimer formation and autophosphorylation without affecting the activity of the phosphorylated Aurora A C290A monomer.(**A**) C290 of monomer I (light pink spheres) packs against Y334 of the αG-helix of monomer II. Other residues within a 4.5 Å radius of C290 in monomer I are shown as red spheres. (**B**) In the monomeric, phosphorylated Aurora A (PDB ID 1OL7), C290 (light orange) does not contact the αG-helix (contact residues within a 4.5 Å radius are shown as orange spheres). (**C**) Sedimentation velocity analytical ultracentrifugation of 100 μM dephosphorylated (deP) Aurora A C290A + 500 μM AMPPCP in kinase assay buffer shows that this protein is predominately monomeric in solution. (**D**) The kinetics of autophosphorylation was monitored by SDS-PAGE and Western blot of 25 μM Aurora A^122−403^ WT or 25 μM Aurora A^125−392^ C290A as described in [Figure 5](#fig5){ref-type="fig"}. C290A mutant has impaired autophosphorylation, but is readily phosphorylated by WT Aurora A. (**E**) Activity of the phosphorylated (P), monomeric C290A towards AP peptide (0.7 ± 0.1 s^−1^) is comparable to that of the WT protein (1.0 ± 0.2 s^−1^).**DOI:** [http://dx.doi.org/10.7554/eLife.02667.017](10.7554/eLife.02667.017)

TPX2^1−25^ is necessary and sufficient for binding to Aurora A {#s2-5}
--------------------------------------------------------------

TPX2^1−43^ had been identified as essential for Aurora A activation and protection from PP1, PP2A, or λPP-directed dephosphorylation ([@bib35]; [@bib100]; [@bib89]). This finding was further substantiated by an X-ray structure of TPX2^1−43^ bound to phosphorylated Aurora A ([@bib9]) ([Figure 7--figure supplement 1](#fig7s1){ref-type="fig"}). In this structure, TPX2^6−23^ was seen in an extended conformation, whereas TPX2^30−43^ formed a regular helix that was proposed to be crucial in protecting Aurora A from phosphatase-mediated T288 dephosphorylation. Surprisingly, in our dimer structure, we could only visualize TPX2^4/6−20/22^ ([Figure 2A,B](#fig2){ref-type="fig"} and [Figure 7--figure supplement 1](#fig7s1){ref-type="fig"}), and the previously seen helical part was completely missing.

To investigate this unexpected result, we designed and functionally characterized the interplay between two peptides, TPX2^1−25^ and TPX2^25−45^, and Aurora A. First, isothermal titration calorimetry (ITC) showed that TPX2^1−25^ bound to Aurora A with the same affinity as longer versions (TPX2^1−147^ or TPX2^1−45^) and did not discriminate between the phosphorylated and dephosphorylated states of the protein ([Figure 7A](#fig7){ref-type="fig"}). On the other hand, no signal was detected for TPX2^25−45^ with Aurora A in ITC. Second, TPX2^1−25^ binding could trigger an increase in activity of dephosphorylated Aurora A towards peptides and autophosphorylation (data not shown). In contrast, TPX2^25−45^ had no effect on Aurora A activity. Third, TPX2^1−25^ could protect Aurora A from λPP-directed dephosphorylation as well as TPX2^1−45^, whereas no protection was found for TPX2^25−45^ ([Figure 7B](#fig7){ref-type="fig"}). These functional data suggest that the first 25 amino acids of TPX2 are primarily responsible for both activation of the enzyme and protection from dephosphorylation.10.7554/eLife.02667.018Figure 7.The N-terminal half of TPX2^1−25^ is the minimal region needed for binding to Aurora A.(**A**) Isothermal titration calorimetry (ITC) measurements conducted with various TPX2 constructs show that TPX2 binds with similar affinity to either the phosphorylated (P) or the dephosphorylated (deP) Aurora A and that the minimal length required for binding encompasses the first 25 residues of TPX2. (**B**) At the functional level, TPX2^1−25^ can protect Aurora A from λ protein phosphatase (λPP)-directed dephosphorylation to the same extent as TPX2^1−45^.**DOI:** [http://dx.doi.org/10.7554/eLife.02667.018](10.7554/eLife.02667.018)10.7554/eLife.02667.019Figure 7---figure supplement 1.The first 25 amino acids of TPX2 bind similarly to either dephosphorylated or phosphorylated Aurora A.Superposition of TPX2 from the dephosphorylated Aurora A (red) + TPX2 (light pink) and the phosphorylated Aurora A (not shown) + TPX2 (magenta) (PDB ID 1OL5) shows that the N-terminal half of TPX2 binds similarly to both proteins whereas the C-terminal half of TPX2 only binds to phosphorylated Aurora A that is monomeric in the X-ray structure, but not to the dimeric, dephosphorylated Aurora A. The dotted line represents missing electron density for residues TPX2^23−29^.**DOI:** [http://dx.doi.org/10.7554/eLife.02667.019](10.7554/eLife.02667.019)10.7554/eLife.02667.020Figure 7---figure supplement 2.Two conserved tyrosines of TPX2 nestled inside a hydrophobic pocket in Aurora A trigger allosteric activation.(**A**) Y8 and Y10 of TPX2 make extensive contacts with residues lining αB- and αC-helices in Aurora A. (**B**) Superposition of TPX2 bound to Aurora A with the C-terminal tails of several AGC kinases reveals equivalent positioning of Phe of the FxxF hydrophobic motifs in the conserved kinases' hydrophobic pockets. Right: a zoom into this highly conserved protein/protein interaction motif used for allosteric regulation. We note that while for most AGC kinases this interaction occurs via its own C-terminal tails, in the evolutionarily younger Aurora A kinase, this regulation is mediated by interaction with a second binding partner, TPX2 ([@bib21]).**DOI:** [http://dx.doi.org/10.7554/eLife.02667.020](10.7554/eLife.02667.020)

The functional role for the first 25 residues in TPX2 makes sense from a comparison to the regulation of other human protein kinases ([@bib42]; [@bib55]; [@bib58]; [@bib6]). This specific interaction between a hydrophobic groove at the junction of the αB/αC-helices in the N-lobe of kinases and a short sequence called 'the hydrophobic motif' (Tyr/Phe-X(X)-Tyr/Phe) from either another partner or from its own C-terminal tail, seems to be a conserved regulatory mechanism across the AGC family ([Figure 7--figure supplement 2](#fig7s2){ref-type="fig"}) ([@bib111]). For CMGC kinases, the hydrophobic groove is occupied by activating cyclin proteins, as originally reported for cyclin binding to the N-lobe of Cdk2 which leads to reorientation of the activation loop and αC-helix into an active conformation ([@bib50]) similar to the effect of TPX2 on Aurora A. In MAPK, activity is increased by binding of the proteins' own C-terminal tails into this hydrophobic groove ([@bib8]). In the tyrosine kinase (TK) family, an N-terminal fragment that precedes the kinase domain of c-KIT, MET, and Ephrin nestles inside the hydrophobic pocket, and autoinhibits the kinases ([@bib15]; [@bib76], [@bib77]; [@bib21]; [@bib25]). In the EGFR members of the TK family, this hydrophobic motif is used as a docking point for kinase activation through dimerization ([@bib112]; [@bib53]). This striking conservation of a very specific recognition mechanism across evolutionarily divergent kinase families suggests that Y8 and Y10 of TPX2 nestled inside the hydrophobic αB/αC pocket in Aurora A are likely the key triggers for kinase activation ([Figure 7--figure supplement 2](#fig7s2){ref-type="fig"}).

Conclusions {#s2-6}
-----------

In this work, we characterized two distinct molecular activation mechanisms of Aurora A: autophosphorylation and allosteric activation through TPX2 binding. Because of the controversy about the autophosphorylation mechanism of protein kinases ([@bib82], [@bib83]; [@bib86]; [@bib64]; [@bib69]; [@bib23]; [@bib48]), we felt the need for multiple lines of evidence. Our aim was to determine the structure of a dephosphorylated enzyme/substrate complex 'ready for autophosphorylation'. The swapped dimer is indeed asymmetric, with one monomer playing the role of the enzyme and the other that of the substrate. In the substrate molecule, the hydroxyl group of T288 is in principle capable of reaching the γ-phosphate of AMPPCP bound to the enzyme monomer as shown by TMD simulations. Domain-swapped dimers have been solved for a number of protein kinases and questioned for their relevance or crystal artifacts ([@bib23]). To address such a critique directly, we showed a long-lived dimer in solution. Importantly, using three biochemical tricks of (i) a mixture between wild type and dead mutant and (ii) a serial dilution, and (iii) a C290A mutant with severely impaired dimer formation and autophosporylation but nearly normal peptide phosphorylation activity in its phosphorylated monomeric state, we could directly demonstrate an intermolecular autophosphorylation mechanism within this long-lived dimer.

Our combined biochemical, thermodynamic, structural, and computational data resolve the controversy about the molecular mechanism(s) of autophosphorylation in Aurora A by directly *measuring the process of autophosphorylation* and linking it to a long-lived functional dimer of dephosphorylated Aurora A. This is in sharp contrast to the mechanism of intramolecular autophosphorylation put forward by [@bib23] based on *measuring the kinetics of peptide phosphorylation* using an automated microchip assay as indirect readout, and not by monitoring autophosphorylation. While the experiments in [@bib23] are conceptually correct, there are a number of errors in the experimental setup and data analysis. Michaelis--Menten equations applied to analyze all data cannot be used because Michaelis--Menten conditions are not met, since the peptide concentration of 3 μM is not much higher than the enzyme concentrations used. Competition of free enzyme for the peptide versus another enzyme molecule is not included in the scheme. The peptide concentration is far below its K~M~ and ATP hydrolysis is faster under these conditions than peptide phosphorylation producing ADP concentrations that cause significant and time-dependent enzyme inhibition (DK, unpublished). Finally, knowledge of the slow dissociation of the dimer and its consequences for the measured kinetics ([Figure 5B](#fig5){ref-type="fig"}) exposes another source for incorrect data interpretation since the experiments in [@bib23] were started by serial dilutions from a high enzyme stock solution. The ongoing discussions on a large collection of functional, structural, and computational data on autophosphorylation in protein kinases underscore both the evolution of differential regulation mechanisms and the difficulty of elucidating these complex biological mechanisms.

Our findings may have more general implications for the family of eukaryotic Ser/Thr kinases. A number of swapped dimer structures have been solved from this enzyme class, and while [@bib23] argued that these dimers are crystallographic artifacts (such as Chk2), our correlation between a domain-swapped dimer and its functional relevance would instead suggest that the reported structures are mechanistically meaningful. For direct evidence the functional relevance of these dimer structures would need to be assessed, as has been reported by elegant experiments for Chk2 ([@bib82]; [@bib86]). Interestingly, most of the known swapped dimers sit in an inactive conformation (using all structural hallmarks for an active kinase discussed in [Figure 2](#fig2){ref-type="fig"}) ([Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}). However, a few dimers capture all active-state structural signatures ([Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}, LOK and Chk2 \[[@bib82]; [@bib86]\]). All previously reported Aurora A dimers are in inactive conformations (PDB IDs 2BMC \[[@bib36]\], 3DJ5, and 3DJ6), while in our new structure both Aurora A molecules are in the active conformation with one monomer serving as the enzyme molecule and the other as the substrate.

The functional effect of autophosphorylation is a 100-fold increase in the catalytic activity of Aurora A. While this catalytic boost is comparable to other Ser/Thr kinases ([@bib44]; [@bib87]; [@bib3]), the more surprising result has been our finding that TPX2 binding activates dephosphorylated Aurora A to similar levels. This is again in contrast to previous reports of additive effects from the two distinct activation mechanisms ([@bib22]). Our results point to a classic allosteric regulation mechanism where either phosphorylation in the activation loop or TPX2 binding in the conserved remote hydrophobic groove shifts the equilibrium far towards the active state.

While the work here has only been concerned with in vitro experiments, it may provide insight into the regulatory roles of Aurora A in the cellular context. Immunofluorescence data have shown that the centrosome-associated Aurora A pool is mainly phosphorylated, whereas the spindle-associated and TPX2-bound Aurora A is dephosphorylated ([@bib101]; [@bib91]; [@bib94]; [@bib110]). In parallel, a recent study on the *Caenorhabditis elegans* homologue of Aurora A kinase, AIR-1, showed that spindle-microtubule associated Aurora A was not phosphorylated and could nonetheless carry on centrosome-independent microtubule formation ([@bib97]). In light of our new findings that TPX2 fully activates dephosphorylated Aurora A, the previous in vivo experiments can be re-interpreted as kinase-activity dependent functions of spindle-microtubule associated Aurora A, and not a kinase-independent function ([@bib97]).

Our in vitro data together with previous in vivo results suggest that nature has evolved two distinct regulation mechanisms for Aurora A in different locations within the cell: autophosphorylation as activation in the centrosomes to promote phosphorylation of downstream targets, and TPX2-mediated activation at the spindle microtubules promoting Aurora A activity to another subset of downstream targets. This hypothesis is supported by the differential timing of Aurora A and TPX2 availability. Aurora A kinase levels are available as early as S-phase and peak in the G2 phase ([@bib24]; [@bib68]). On the other hand, TPX2 levels peak in the prometaphase/spindle formation stage that follows the G2 phase ([@bib43]; [@bib26]; [@bib72]). Our findings help shed light on an elegant strategy for fine-tuning cellular kinetics that provides more complex regulation in higher organisms.

We finally want to raise the question whether Aurora A autophosphorylation is physiologically relevant in cells or whether phosphorylation-mediated activation is primarily accomplished by upstream kinases. While we do not have a conclusive answer to this challenging question, which has been tackled for a number of other protein kinases, we discuss several conjectures. Although the upstream PAK1 kinase can phosphorylate Aurora A at T288, autophosphorylation appears to be the essential mode of activation because PAK1 inhibition does not abolish cell division but Aurora A inhibitors do ([@bib114]; [@bib68]; [@bib57]). Are the in vitro autophosphorylation kinetics reported here compatible with the known phosphorylation kinetics of Aurora A during the cell cycle? Our data imply that the initial rate of Aurora A autophosphorylation is very slow because this reaction occurs via the long-lived swapped dimer between two dephosphoryated Aurora A molecules. Further autophosphorylation displays a strong sigmoidal character revealing much faster kinetics of Aurora A phosphorylation by an already phosphorylated Aurora A molecule ([Figures 5 and 6](#fig5 fig6){ref-type="fig"}). In light of the increased local concentration of Aurora A in the centrosomes ([@bib41]) (although the exact concentration is not known), our measured autophosphorylation kinetics is qualitatively in line with the progression of Aurora A T288 phosphorylation during the 3--4 h of G2/M duration in HeLa cells at 37°C ([@bib19]; [@bib65]; [@bib81]).

Materials and methods {#s3}
=====================

Cloning and purification of Aurora A kinase {#s3-1}
-------------------------------------------

TEV-cleavable, His6-tagged Aurora A kinase, either long (122--403) or short (125--392) constructs, were cloned into pET28a and expressed in Rosetta 2 (DE3) *E. coli* cells (Stratagene) for 13--15 h at 21°C. Cells were centrifuged at 5000 rpm for 15 min, resuspended in buffer A, and sonicated in the presence of EDTA-free protease inhibitor cocktail and DNAse for 4 min (20 s on, 20 s off, 3.0 V). Lysates thus obtained were filtered using a 0.22 μm filtering unit and passed through a NiNTA column. The protein was eluted at 20% buffer B and Aurora A kinase fractions were pooled and TEV-cleaved overnight at 4°C in a 5 kDa dialysis cassette that was exchanged against buffer C. Cleaved Aurora A was passed through another nickel column to remove any uncleaved reactants and His6-TEV-protease, and then purified to homogeneity through a 26/60 S200 size exclusion column. Protein thus produced was aliquoted and flash-frozen before being stored at −80°C and used for kinase assays. Mutant Aurora A^122−403^ T288V was also purified the same way. The phosphorylation of all Aurora A samples including mutant forms used here were quantitatively confirmed by mass spectrometry (MS).

Dephosphorylated Aurora A kinase was obtained through a λPP co-expression system. Codon-optimized Aurora A^122−403^ in pET28a and untagged λPP in T7-7 plasmid were co-transformed in BL21(DE3) cells and spread on Kan/Amp 2× YT plates. The most robust colony was used for a 2× YT pre-culture and later on to inoculate a 1 L culture to an OD of 0.2. Cells were induced with 0.6 mM IPTG for 5 h at 37°C. It was noticed that although Aurora A could grow reasonably well in LB media, λPP could not; hence, the choice of 2× YT media for all co-expression needs. Purification involved the NiNTA column, followed by overnight TEV cleavage and GST-λPP treatment, in tandem NiNTA-GST columns and finally a 26/60 S200 size exclusion column. MS was used to confirm that Aurora A kinase was completely dephosphorylated. At the end of the purification, Aurora A was dialyzed against buffer C, flash-frozen with liquid nitrogen into 1 mL aliquots and stored at −80°C.

The buffers used were:Buffer A: 50 mM TrisHCl (pH 8.0), 300 mM NaCl, 40 mM imidazole, 20 mM MgCl~2~, 10% (vol/vol) glycerolBuffer B: 50 mM TrisHCl (pH 8.0), 300 mM NaCl, 500 mM imidazole, 20 mM MgCl~2~, 10% (vol/vol) glycerolBuffer C: 20 mM TrisHCl (pH 7.0), 200 mM NaCl, 20 mM MgCl~2~, 5 mM TCEP, 10% (vol/vol) glycerolBuffer D: 135 mM NaCl, 3 mM KCl, 8 mM Na~2~HPO~4~, 1.5 mM KH~2~PO~4~, 5 mM TCEP, 10% (vol/vol) glycerol, pH 7.40Buffer E: 135 mM NaCl, 3 mM KCl, 8 mM Na~2~HPO~4~, 1.5 mM KH~2~PO~4~, 5 mM TCEP, 10% (vol/vol) glycerol, 10 mM glutathione, pH 7.40

Typical yields were 8--10 mg of phosphorylated Aurora A and 45--50 mg of dephosphorylated Aurora A (expressed in the presence of λPP) per liter of *E. coli* culture.

Mass spectrometry {#s3-2}
-----------------

The LCMS system consisted of an Agilent 1200 series HPLC connected to an Agilent series 6520 ESI Q-TOF. Protein samples (10 µM) dissolved in a 5% acetonitrile--0.1% formic acid buffer were separated on a C18 Poroshell 300SB column (1 mm × 75 mm × 5 µm) at 0.5 mL min^−1^ using a linear gradient of 5--70% acetonitrile in 0.1% formic acid. MS data were collected up to 3000 m/z and raw spectra were deconvoluted using the maximum entropy algorithm of Agilent Masshunter version B.03.01 software. External mass calibration was performed using a mixture of purine (121 m/z) and HP-0921 (922 m/z) immediately prior to measuring protein samples.

In vitro kinase assays {#s3-3}
----------------------

Aurora A, either phosphorylated/dephosphorylated wild type or mutant protein, was mixed with either AP (APSSRRTTLCGTL), Kemptide (LRRASLG), or Lats2 (ATLARRDSLQKPGLE), in the absence or presence of 50 μM TPX2 in kinase buffer (20 mM TrisHCl, 200 mM NaCl, 3% \[vol/vol\] glycerol, 20 mM MgCl~2~, 1 mM TCEP, pH 7.50). These substrates comprise the consensus sequence for Aurora A (\[R/K/N\]-R-X-\[S/T\]-B where B is any hydrophobic residue with the exception of Pro) ([@bib38]; [@bib81]; [@bib88]). Peptides were ordered through Genscript. The reaction was initiated with the addition of 5 mM ATP. Then 5 μl time points were collected, resuspended in 10 μl 6% (vol/vol) trichloroacetic acid (in water) to quench the reaction, and neutralized with 50 μl 100 mM KH~2~PO~4~, pH 8.0 to provide the appropriate pH for nucleotide separation. The mixture was then passed through a 0.22 μm SpinX column to remove any protein precipitation. Reverse phase-high performance liquid chromatography (RP-HPLC) and an ACE 5 C18-AR, 100 Å pore size column, were used to separate nucleotides as well as peptides. For nucleotide runs, 2 μl of the aforementioned mixture was sufficient for analysis, whereas for the peptide runs the optimal injection volume was 20 μl. Nucleotide runs were routinely performed to ensure no unproductive hydrolysis was occurring during the experiment. An isocratic elution run in 100 mM KH~2~PO~4~, pH 6.0 was performed for this purpose. For the peptide runs, a gradient of 0--30% of elution buffer lasting 10 min at 0.4 mL/min was sufficient to separate phosphorylated from non-phosphorylated species. The running buffer was 0.1% TFA (vol/vol) in water, while the elution buffer was 100% acetonitrile. Representative peptide RP-HPLC traces are shown in [Figure 1--figure supplement 5](#fig1s5){ref-type="fig"}. Lastly, to ensure full saturation of Aurora A by TPX2 and test these proteins were well behaved, a dose-dependence curve of the effect of TPX2 on Aurora A as shown in [Figure 1--figure supplement 6](#fig1s6){ref-type="fig"} was obtained.

Isothermal titration calorimetry {#s3-4}
--------------------------------

All titrations were carried out using Nano ITC (TA Instruments) and analyzed via the NanoAnalyze software using the independent fit model. Injectant was added in 1 μl volume, every 180 s, with a constant stirring speed at 350 rpm and at 25°C. Prior to ITC titration, both protein and peptide were dialyzed/resuspended in 20 mM TrisHCl, 200 mM NaCl, 3% (vol/vol) glycerol, 1 mM TCEP, pH 7.50. The concentrations used for each of the runs in [Figure 7A](#fig7){ref-type="fig"} were: 35 μM dephosphorylated (deP) A^122−403^ + 280 μM TPX2^1−147^, 48 μM deP A^122−403^ + 680 μM TPX2^1−45^, 13 μM deP A^122−403^ + 250 μM TPX2^1−25^, 18 μM deP A^122−403^ + 250 μM TPX2^25−45^, 20 μM phosphorylated (P) A^122−403^ + 280 μM TPX2^1−147^, 90 μM P A^122−403^ + 940 μM TPX2^1−45^, 20 μM P A^122−403^ + 300 μM TPX2^1−25^, and 18 μM P A^122−403^ + 300 μM TPX2^25−45^.

Crystallographic methods {#s3-5}
------------------------

Crystals of dephosphorylated Aurora A^122−403^ in complex with AMPPCP and TPX2^1−45^ were grown at 18°C by vapor diffusion and the hanging drop method. A 2:1 ratio of protein mixture:mother liquor was obtained by combining 300 μM (10 mg/ml) deP Aurora A^122−403^ + 1.5 mM AMPPCP + 300 μM TPX2^1−45^ with 0.2 M lithium sulfate monohydrate, 0.1 M BisTris, pH 5.5, 25% PEG3350. Similarly, crystals of dephosphorylated Aurora A^122−403^ in complex with AMPPCP were obtained by mixing a 2:1 ratio of 570 μM (18 mg/ml) deP Aurora A^122−403^ + 1 mM AMPPCP with mother liquor (0.2 M ammonium sulfate, 0.2 M TrisHCl, pH 7.50, 30% (wt/vol) PEG3350). These latter crystals were also grown at 18°C by vapor diffusion and the hanging drop method. The protein, peptide, and nucleotide were originally stored in 20 mM TrisHCl, 200 mM NaCl, 10% (vol/vol) glycerol, 20 mM MgCl~2~, 1 mM TCEP, pH 7.50.

Diffraction data were collected at 100 K at Advanced Light Source (Lawrence Berkeley National Laboratory) beamlines (8.2.1 and 8.2.2). The details of data collections are listed in [Table 1](#tbl1){ref-type="table"}. Data were processed with the automated data reduction program X[ia]{.smallcaps}2 ([@bib108]) that is part of the CCP4 suite ([@bib107]) and uses iMOSFLM ([@bib7]) for integration and Scala ([@bib31]) for scaling. Initial phases were obtained by molecular replacement (CCP4 program M[olrep]{.smallcaps} \[[@bib103]\]) by using an Aurora A kinase structure (PDB ID 1MQ4) as a search model. The refinement was carried out with REFMAC5 ([@bib79]) and [phenix.refine]{.smallcaps} ([@bib2]), followed by manual rebuilding in C[oot]{.smallcaps} ([@bib27]; [@bib28]).

Analytical ultracentrifugation {#s3-6}
------------------------------

Sedimentation velocity runs were performed on a Beckman Optima XL-A Analytical Ultracentrifuge at 50,000 rpm and 18°C (same as crystallization temperature). Sedimentation of 100 μM deP Aurora A^122−403^ (or 150 μM deP Aurora A^122−403^, or 160 μM Aurora A^125−392^ D274A, or 100 μM Aurora A^125−392^ C290A) + 500 μM AMPPCP and/or 100 μM TPX2^1−25^ was followed at three different wavelengths (285 nm, 290 nm, and 295 nm). Data were analyzed using the SEDFIT software ([@bib90]; [@bib20]) and the continuous size-distribution option.

Small-angle X-ray scattering (SAXS) {#s3-7}
-----------------------------------

All SAXS experiments were done on a BioSAXS-1000 system at Brown University, Providence, RI, USA (camera length 480.3 mm, Pilatus 100 K detector). SAXS data were recorded for Aurora A at concentrations between 0.33 and 6.6 mg/ml at 20°C with 1 mg/mL TPX2^1−25^ each. The momentum transfer axis (s = 4πsinθ/λ, where 2θ represents the scattering vector s and λ = 1.54187 nm) was calibrated by using silver behenate as standard. The experiment time was between 15 min and 6 h per sample, depending on the protein concentration. Data reduction of the raw image files and conversion into scattering curves was done with the SAXSLab software (Rigaku). The SAXS curves were further processed (buffer subtraction, correction for unbound TPX2) with the program P[rimus]{.smallcaps} ([@bib60]). We used calculated SAXS curves (program C[rysol]{.smallcaps} \[[@bib95]\]) from the X-ray structures of this study as reference for the monomeric and dimeric state. The amount of dimers was calculated by using a script based on the least squares method calculations.

Targeted molecular dynamics simulations {#s3-8}
---------------------------------------

The crystal structure of dephosphorylated Aurora A bound to AMPPCP and TPX2 (PDB ID 4C3P) was used as the starting point for building the model presented in [Figure 3B](#fig3){ref-type="fig"}. The electron density for the amino acids in the region 283--288 of monomer II was not distinguishable from noise. We used the tools in the software package Modeller 9.11 ([@bib30]) to model the missing residues. The lowest energy model was then used as the starting point for a molecular dynamics simulation run, in which the distance between the oxygen in the sidechain hydroxyl group of T288 and the γ-phosphate of the AMPPCP moiety bound to monomer I was reduced to 3 Å. To achieve this, the structure was parameterized with the CHARMM 22-protein all-atom force field with the CMAP backbone energy correction ([@bib70], [@bib71]). The system was solvated in a rectangular box with TIP3 water molecules and neutralized with NaCl counterions. The final simulation box contained approximately 65,000 atoms. Periodic boundary conditions were applied to the simulation box.

After energy minimization, the simulation box was gradually heated to 300 K with a time step of 1 fs while gradually reducing positional restraints in an MD simulation of 2 ns with the software NAMD 2.8 ([@bib85]). The system was then equilibrated for 10 ns in the NPT ensemble (T = 300 K, p = 1.01325 bar) with the software NAMD, using the Langevin dynamics method for controlling temperature, and the combined Langevin piston Nose--Hoover method for equilibrating pressure ([@bib75]; [@bib37]). We then used the software GROMACS 4.5.5 ([@bib47]) with the steered molecular dynamics functionality as implemented in the extension PLUMED 1.3 ([@bib12]) to progressively reduce the distance between the hydroxyl group of T288 and the γ-phosphate of the AMPPCP moiety bound to monomer I. This distance was reduced to 3 Å within a simulation run of 2 ns.
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Thank you for sending your work entitled "Molecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2" for consideration at *eLife*. Your article has been favorably evaluated by a Senior editor and 3 reviewers, one of whom, Philip Cole is a member of our Board of Reviewing Editors.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

The manuscript by Zorba et al is a multifaceted study aimed at clarifying the roles of autophosphorylation and TPX2 mechanisms of activation of the Aurora A kinase (AAK) as well as the molecularity of autophosphorylation of AAK. Several key findings include:

1\) The stimulation by AAK autophosphorylation of Thr288 (by 100-fold) is roughly matched by TPX2 stimulation of unphosphorylated AAK (by 40-fold)

2\) The domain swapped dimer of the unphosphorylated AAK in the presence of TPX2 represents a possible interaction of intermolecular autohosphorylation.

3\) The solution phase assays especially with a dead mutant as substrate demonstrate the kinetic competence of intermolecular autophosphorylation.

Additional bolstering data include molecular modeling showing how the disordered loop in monomer II of AAK could be positioned for phosphoryl transfer in the active site of monomer I of AAK, analytical ultracentrifugation and SAXS showing the presence of a minor population of solution phase dimer in AAK, and ITC and enzymatic experiments demonstrating that aa1-25 of TPX2 are necessary and sufficient for high affinity binding (ca 2 uM) and activation. The careful use of Abs and mass spec really help to provide quantitative information about the state of Thr288 phosphorylation in the various enzyme forms. Importantly, the results here fill gaps in the literature about AAK regulation and contradict those from a recent study from Dodson et al reporting that AAK autophosphorylation is intramolecular. Zorba et al point out several limitations in Dodson et al that can account for the differing conclusions. Overall, Zorba et al is carefully executed, well-written, and makes a set of significant findings that should interest a broad readership. We ask the authors to address the issues below.

1\) A missing piece that if added would significantly enhance this study relates to the structural basis of AAK autophosphorylation. The domain swapped AAK dimer shows surfaces of interaction in the C-lobes that one assumes are important for intermolecular autophosphorylation if the authors\' model is correct. It would be very useful to mutagenize these contacting residues to ascertain their contributions to the kinetics of AAK autophosphorylation. A hypothesis to be tested would be that once autophosphorylation is completed (even if slower in such contact mutants), activity of such AAK mutants with peptide substrates would be near normal.

2\) The data in [Figure 5B](#fig5){ref-type="fig"} at 1 µM AAK suggests a half-life of at least 400 seconds. This would predict a half-life of at least 4000 seconds (67 minutes) at 100 nM. These slow rates invite concerns about the physiologic significance of autophosphorylation as an activation mechanism of AAK rather than its activation by an upstream kinase such as PAK1 or CDK11. On the other hand, it appears that the assays were carried out at 25°C, which could slow things down. Moreover, the local effective concentration of AAK may be higher than its total cellular concentration. We hope that the authors can provide a perspective on whether the preponderance of existing evidence supports that AAK autophosphorylation is relevant to AAK\'s normal cellular function.
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*1) A missing piece that if added would significantly enhance this study relates to the structural basis of AAK autophosphorylation. The domain swapped AAK dimer shows surfaces of interaction in the C-lobes that one assumes are important for intermolecular autophosphorylation if the authors\' model is correct. It would be very useful to mutagenize these contacting residues to ascertain their contributions to the kinetics of AAK autophosphorylation. A hypothesis to be tested would be that once autophosphorylation is completed (even if slower in such contact mutants), activity of such AAK mutants with peptide substrates would be near normal*.

This is a very good suggestion that would provide compelling additional evidence for the functional role of the swapped dimer. We had originally thought about this experiment but were discouraged by the fact that most of the intermolecular interactions for the dimer are present as corresponding intramolecular contacts in the monomer and by our pervious failure to disrupt a dimer interface in another kinase. Challenged by the reviewers, we gave this experiment a try and to our pleasant surprise it worked quite cleanly with the C290A mutation. Residue C290 makes different contacts in the swapped dimer relative to the monomer, and we therefore speculated that a mutation in this position might not be too disruptive to the monomer fold and activity.

The C209A mutant is predominantly monomeric (by AUC) and indeed severely hampered in its autophosphorylation. As logically reasoned by the referees, the activity of the phosphorylated C290A mutant towards peptide substrates is comparable to the WT protein. We added these new data and the interpretation to the manuscript (in the Results and Discussion section of the manuscript and [Figure 6](#fig6){ref-type="fig"}).

*2) The data in* [*Figure 5B*](#fig5){ref-type="fig"} *at 1 µM AAK suggests a half-life of at least 400 seconds. This would predict a half-life of at least 4000 seconds (67 minutes) at 100 nM. These slow rates invite concerns about the physiologic significance of autophosphorylation as an activation mechanism of AAK rather than its activation by an upstream kinase such as PAK1 or CDK11. On the other hand, it appears that the assays were carried out at 25°C*, *which could slow things down. Moreover, the local effective concentration of AAK may be higher than its total cellular concentration. We hope that the authors can provide a perspective on whether the preponderance of existing evidence supports that AAK autophosphorylation is relevant to AAK\'s normal cellular function*.

This is an excellent point! Although we do not have a definite answer to this challenging but crucial question, we have added one paragraph to the end of the Conclusion rationalizing that autophosphorylation could conceivably be a major mechanism in vivo.

A\) Pak1 inhibition only delays the cell cycle, but does not arrest it and does not lead to cell death, in contrast to specific Aurora A kinase inhibitors that do.

B\) As rationalized by the referees, the increased local concentration of Aurora A and the increased cellular temperature conjectures that our in vitro-measured autophosphorylation kinetics at 25°C are compatible with known Aurora A T288 phosphorylation kinetics during the 3 to 4 hours of G2/M duration in HeLa cells.

Furthermore we discuss the strong sigmoidal phosphorylation kinetics measured in our manuscript as additional evidence.

[^1]: These authors contributed equally to this work.

[^2]: New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), Daegu, Korea.

[^3]: Values in parentheses correspond to the highest-resolution shell.

[^4]: deP: dephosphorylated; PBD, Protein Data Bank.
